Physician profile
Dee Ann Guy
NPI 1396150116
$13,509.74
in general payments reported to CMS, 2019-2025
68 companies · $3,451 in 2025
The $3,451 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,045 · 2022: $2,221 · 2023: $2,605 · 2024: $3,187 · 2025: $3,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,490 · Consulting Fee: $555 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,489.87 |
| Consulting Fee | $555.00 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,383.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $869.78 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Pfizer INC. | $681.96 | 2021-2025 | |
| Daiichi Sankyo INC. | $681.47 | 2021-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $652.06 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Incyte Corporation | $609.36 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Seagen INC. | $543.04 | 2021-2025 | Padcev, Tukysa, Adcetris |
| Merck Sharp & Dohme LLC | $465.14 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Amgen INC. | $432.21 | 2021-2023 | Lumakras, Kyprolis |
| Glaxosmithkline, LLC. | $417.75 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Janssen Biotech, INC. | $361.22 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Genzyme Corporation | $289.70 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $265.80 | 2022-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Celgene Corporation | $252.21 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $243.60 | 2021-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $238.86 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Array Biopharma INC | $225.47 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Blueprint Medicines Corporation | $206.53 | 2021-2025 | Ayvakit |
| Stemline Therapeutics INC. | $205.66 | 2023-2025 | Orserdu |
| Gilead Sciences, INC. | $204.56 | 2021-2025 | Trodelvy |
| Abbvie INC. | $199.02 | 2024-2025 | |
| Genentech USA, INC. | $184.80 | 2022-2025 | Venclexta, Polivy, Columvi |
| Kite Pharma, INC. | $171.84 | 2021-2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $169.66 | 2021-2025 | |
| Beone Medicines USA, INC. | $166.76 | 2025 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $152.86 | 2024-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $142.00 | 2021-2025 | Libtayo, Lynozyfic |
| Deciphera Pharmaceuticals INC. | $137.72 | 2021-2025 | Qinlock, Romvimza |
| Karyopharm Therapeutics INC. | $130.32 | 2021-2025 | Xpovio |
| Myriad Genetic Laboratories, INC. | $115.43 | 2021-2024 | Bracanalysis Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.67 | 2021-2025 | Gilotrif |
| Beigene USA, INC. | $109.14 | 2022-2024 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $105.50 | 2021-2023 | Imbruvica, Epkinly |
| Alexion Pharmaceuticals, INC. | $100.67 | 2022-2025 | Ultomiris, Soliris |
| Jazz Pharmaceuticals INC. | $91.78 | 2022-2024 | |
| Astellas Pharma US INC | $90.42 | 2021-2025 | Xtandi, Padcev |
| Progenics Pharmaceuticals, INC. | $71.34 | 2021-2025 | Pylarify |
| Agios Pharmaceuticals, INC. | $70.16 | 2022-2025 | Pyrukynd |
| Sumitomo Pharma America, INC. | $68.15 | 2024-2025 | Orgovyx |
| Adc Therapeutics America, INC. | $67.61 | 2021-2022 | |
| Emd Serono, INC. | $52.64 | 2023-2024 | Bavencio |
| Acrotech Biopharma INC. | $47.45 | 2021-2025 | Beleodaq |
| Taiho Oncology, INC. | $46.71 | 2023-2025 | |
| Myovant Sciences INC. | $44.69 | 2022 | |
| Sobi, INC | $44.15 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $43.32 | 2024-2025 | Monoferric |
| Genmab U.S., INC. | $39.09 | 2024-2025 | Epkinly |
| Mirati Therapeutics, INC. | $37.77 | 2023-2024 | Krazati |
| Exelixis INC. | $36.46 | 2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $35.93 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $35.87 | 2022-2023 | Rezlidhia, Tavalisse |
| Morphosys, US INC. | $34.64 | 2022 | |
| Immunocore Limited | $29.53 | 2025 | Kimmtrak |
| Aveo Pharmaceuticals, INC. | $28.76 | 2025 | |
| Tersera Therapeutics LLC | $27.00 | 2025 | Quzyttir |
| Eusa Pharma (US) LLC | $23.41 | 2021 | |
| Novocure INC. | $22.99 | 2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $21.38 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $20.62 | 2022 | |
| Kyowa Kirin, INC. | $20.16 | 2025 | |
| Coherus Oncology, INC. | $19.59 | 2025 | Loqtorzi |
| Dova Pharmaceuticals | $19.29 | 2021 | |
| Spectrum Pharmaceuticals INC. | $17.75 | 2025 | Rolvedon |
| Caris Mpi, INC. | $17.16 | 2025 | Mi Cancer Seek |
| Adaptive Biotechnologies Corporation | $15.05 | 2024 | Clonoseq |
| Puma Biotechnology, INC. | $14.77 | 2022 | |
| Geron Corporation | $14.61 | 2025 | Rytelo |
| Global Blood Therapeutics, INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
Fabhalta $684Enhertu $556Jakafi $296Imfinzi $294Kisqali $293Keytruda $263Scemblix $246Opdivo $226Xtandi $214Braftovi $212Mektovi $212Orserdu $206Orgovyx $206Sarclisa $205Lynparza $185Imbruvica $184Brukinsa $181Verzenio $180Lorbrena $175Pluvicto $174Padcev $166Ayvakit $165Jaypirca $163Besremi $153Epkinly $151Adcetris $144Lenvima $143Talzenna $139Monjuvi $138Ojjaara $137Tukysa $136Xalkori $132Venclexta $118Elrexfio $112Trodelvy $107Tasigna $103Jemperli $96.36Darzalex $96.17Inlyta $92.45Opdualag $86.06Qinlock $84.46Fruzaqla $82.14Polivy $80.88Alunbrig $79.31Nubeqa $78.35Bracanalysis Cdx $74.26Calquence $74.15Injectafer $71.81Ultomiris $71.16Tevimbra $69.59Reblozyl $68.55Talvey $65.50Stivarga $64.57Promacta $63.68Xpovio $63.41Tecvayli $62.33Zejula $60.93Yescarta $59.86Oxbryta $58.87Pyrukynd $57.76Bosulif $53.90Elahere $53.22Libtayo $52.87Krazati $52.70Retevmo $51.24Zepzelca $51.11Lumakras $50.28Carvykti $50.23Ninlaro $48.55Inqovi $46.71Lonsurf $46.71Monoferric $43.32Bavencio $42.74Pomalyst $42.49Zynyz $42.07Vitrakvi $40.89Lutathera $40.35Blenrep $39.90Besponsa $36.55Tivdak $36.49Cabometyx $36.46Pylarify $36.32Tibsovo $35.93Pemazyre $35.90Akeega $35.86Balversa $35.86Erleada $35.86Rybrevant $34.69Comirnaty $33.83Paxlovid $33.83Datroway $33.18Romvimza $32.26Kimmtrak $29.53Iclusig $29.37Fotivda $28.76Mekinist $27.57Quzyttir $27.00Keytruda Qlex $24.04Gilotrif $23.54Optune Lua (Novottf-200t) $22.99
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dee Guy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.